Cell therapy (CAR-T) · Kills target cells, directed at CD70 and T-cell receptor (TCR) · developed by CRISPR Therapeutics
Volamcabtagene durzigedleucel is an allogeneic T-lymphocyte cell therapy gene-edited with CRISPR-Cas9 to disrupt endogenous TCR and MHC class I expression and to express a chimeric antigen receptor specific for CD70. The CAR-T cells recognize and bind CD70-overexpressing tumor cells, mediating their cytotoxic killing. It is being studied in T-cell lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04502446 | Phase 1 | T Cell Lymphoma | Terminated | CRSP |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
T Cell Lymphoma
Updated Nov 8, 2026. Something wrong or missing? Report it on the CRSP page.
See CRSP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CRSP catalysts and pipeline →